Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Investigation of CAR T-cell Therapy in Earlier Treatment Lines Could Continue to Alter Treatment Sequencing in Myeloma

May 22nd 2023

Faculty from an OncLive® Institutional Perspectives in Cancer webinar on multiple myeloma summarize the main messages from their presentations.

OncLive Honors 12 Cancer Care Pioneers

May 22nd 2023

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Dr Mohan on CAR T-cell Therapies and Bispecific Antibodies in R/R Multiple Myeloma

May 19th 2023

Meera Mohan, MD, MS, FACP, discusses the significance of CAR T-cell therapies and bispecific antibodies in patients with relapsed/refractory multiple myeloma.

Dr Bal on Ide-cel in R/R Multiple Myeloma

May 18th 2023

Susan Bal, MD, assistant professor, University of Alabama at Birmingham, discusses key efficacy and safety data from the phase 2 KarMMa trial in patients with relapsed/refractory multiple myeloma.

Dr Suvannasankha on the Potential Mitigation of CRS With REGN5459 in R/R Myeloma

May 17th 2023

Attaya Suvannasankha, MD, discusses addressing the incidence of cytokine release syndrome in a first-in-human phase 1/2 trial for patients with relaped/refractory multiple myeloma.

Dr Bal on Unmet Needs With CAR T-cell Therapy in Multiple Myeloma

May 15th 2023

Susan Bal, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

Dr Zonder on the Management of Bispecific Antibody–Associated Toxicities in Multiple Myeloma

May 12th 2023

Jeffery Zonder, MD, discusses the management of toxicities associated with bispecific antibodies in patients with multiple myeloma.

Dr Mohan on AEs Associated With CAR T-cell Therapy in R/R Myeloma

May 10th 2023

Meera Mohan, MD, MS, FACP, discusses adverse effects associated with CAR T-cell therapy in relapsed/refractory multiple myeloma.

Unpacking the Implications of CAR T-cell Therapy for Patients With Multiple Myeloma

May 9th 2023

Abhinav Deol, MD, gives insight on CAR T-cell therapy’s future role in the treatment landscape for multiple myeloma and what needs to be done to push the needle forward.

REGN5459 Demonstrates Early Promise in Heavily Pretreated Multiple Myeloma

May 9th 2023

Attaya Suvannasankha, MD, discusses the unique mechanism of action of REGN5459, the early efficacy and safety of the immunotherapy in heavily pretreated patients with relapsed/refractory multiple myeloma, and opportunities for further exploration.

Dr Bal on the Evolution of CAR T-cell Therapy in Multiple Myeloma

May 8th 2023

Susan Bal, MD, discusses the evolution of CAR T-cell therapy in multiple myeloma.

Dr Mohan on Toxicities Associated With T-cell–directed Therapy in Myeloma

May 4th 2023

Meera Mohan, MD, MS, FACP, discusses the toxicities associated with T-cell–directed therapies in relapsed/refractory multiple myeloma.

Dr Suvannasankha on Bispecific Antibodies in Multiple Myeloma

April 27th 2023

Attaya Suvannasankha, MD, discusses future research directions with bispecific antibodies in patients with multiple myeloma and potential methods for mitigating adverse effects in this population.

Dr Tauro on the Role of ULK3 in Multiple Myeloma

April 26th 2023

Marilena Tauro, PhD, discusses the role for ULK3 in regulating autophagy in multiple myeloma.

Leaked Data Show Cilta-cel Delivers 74% Reduction in Risk of Progression in Early Relapsed/Refractory Myeloma

April 20th 2023

Leaked data from an abstract scheduled to be presented at the 2023 EHA Hybrid Congress showed that ciltacabtagene autoleucel demonstrated a 74% reduction in the risk of disease progression or death compared with standard therapy in patients with relapsed/refractory multiple myeloma who received 1 to 3 prior lines of therapy.

Dr Suvannasankha on the Safety/Efficacy of REGN5459 in R/R Multiple Myeloma

April 18th 2023

Attaya Suvannasankha, MD, discusses the safety and efficacy of REGN5459, a BCMAxCD3 bispecific antibody with low affinity to CD3 on T cells, in relapsed/refractory multiple myeloma.

REGN5459 Delivers Dose-Dependent Responses in Relapsed/Refractory Myeloma

April 17th 2023

The BCMA- and CD3-directed bispecific antibody REGN5459 led to fast onset, deep, and dose-dependent responses sustained over time, with a high frequency of manageable low-grade cytokine release syndrome in patients with relapsed/refractory multiple myeloma.

FDA Accepts sBLA for Ide-cel in Triple-class Exposed Relapsed/Refractory Myeloma

April 17th 2023

The FDA has accepted a supplemental biologics license application seeking the approval of idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma who have received an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

FDA Grants Orphan Drug Designation to OM-301 in Multiple Myeloma

April 13th 2023

The FDA has granted an orphan drug designation to OM-301 for the treatment of patients with multiple myeloma.

Dr Godara on the Selection of CAR T-Cell Therapies vs Bispecific Antibodies in R/R Multiple Myeloma

April 13th 2023

Amandeep Godara, MBBS, discusses important patient factors to consider when deciding between a CAR T-cell therapy vs bispecific antibody in relapsed/refractory multiple myeloma, and the importance of mitigating treatment-related toxicities associated with the administration of bispecific antibodies in this disease setting.